Stay updated on Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial
Sign up to get notified when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.

Latest updates to the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedA dedicated Locations section now lists Ontario as a study site. The page footer shows Revision: v3.3.3, and the old Ontario Locations entry and the HHS Vulnerability Disclosure note were removed.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedAdded a minor site revision note: 'Revision: v3.3.2' replacing the previous 'Revision: v3.3.1' on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check38 days agoChange DetectedPage footer revision updated from v3.2.0 to v3.3.1. The study content and user-facing functionality remain unchanged.SummaryDifference0.1%

- Check46 days agoChange DetectedRemoved the government funding lapse notice about NIH operating status from the page; this is a non-critical notice and does not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check60 days agoChange DetectedNo significant additions or deletions were detected; core study details, eligibility criteria, and locations appear unchanged.SummaryDifference0.5%

- Check88 days agoChange DetectedUpdate includes a critical operating status notice and a new software version (v3.2.0), indicating updated deployment with potential service impact; previous version reference (v3.1.0) was removed.SummaryDifference4%

Stay in the know with updates to Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.